President & CEO, John Sell, details his predictions for the greater logistics industry moving forward in 2024. Read the full article…
CUSTOMIZED SUPPLY CHAIN SOLUTIONS
President & CEO, John Sell, details his predictions for the greater logistics industry moving forward in 2024. Read the full article…
We are pleased to announce leadership changes within the MD Logistics quality department. Tenured Director of Quality, Robert Grange, will be leaving MD Logistics to enter retirement, with Cheyanne Morrison succeeding. Read the full article…
As advancements in reusable shipping technology have been made, these products are becoming an attractive alternative to traditional shipping methods for those in the life sciences and pharmaceuticals industry. Read the full article…
While there are many different things that could disrupt the flow of the supply chain, the world witnessed first hand, the impact the COVID-19 pandemic had on the global supply chain. The pandemic also altered access to an available labor pool for the 3PL provider. The ability to flex labor across all areas of the business, have helped to alleviate the shortage and maintain the level of service our customers have come to expect from us. Read the full article…
Serialization is here to stay. So how can you turn your gold mine of serialization data into the backbone of your digital transformation? Read the full article…
Often, 3PL providers will specialize in and target a specific industry, geographical market, or service offerings. Logistics providers who specialize by industry or service are referred to as niche 3PL’s. Read the full article…
Here are the steps that life science and healthcare companies are taking to embrace digital transformation. Read the full article…
MD Logistics, an Indiana based 3PL firm headquartered in Plainfield, announced the addition of a fourth facility, creating up to 50 new Hoosier jobs by the end of 2023. Read the full article…
As we start another year, we look back on the amazing year 2018 was, and forward in excited anticipation for what challenges and opportunities 2019 will bring our way. Read the full article…
Public criticism and scrutiny from lawmakers will likely remain, keeping biotech and pharma under pressure. At the same time, a cooperative FDA and scientific advances in oncology, cell and gene therapy should continue to serve as a tailwind, generating new approvals and investor optimism. Digital opportunities, including in artificial intelligence, have also proved attractive to drugmakers, spurring changes among executive teams. Here are seven trends to watch as 2019 unfolds… Read the full article…